These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 35307793)

  • 21. Initiation of Levodopa-Carbidopa Intestinal Gel Infusion Using Telemedicine (Video Communication System) Facilitates Efficient and Well-Accepted Home Titration in Patients with Advanced Parkinson's Disease.
    Willows T; Dizdar N; Nyholm D; Widner H; Grenholm P; Schmiauke U; Urbom A; Groth K; Larsson J; Permert J; Kjellander S
    J Parkinsons Dis; 2017; 7(4):719-728. PubMed ID: 28984615
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Determination of the motor status of patients with advanced Parkinson's disease under levodopa-carbidopa intestinal gel using a machine learning model.
    Efthymiopoulou E; Antonoglou A; Loupo B; Bougea A
    Acta Neurol Belg; 2023 Apr; 123(2):565-570. PubMed ID: 36472797
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-term effect of levodopa-carbidopa intestinal gel on axial signs in Parkinson's disease.
    Fabbri M; Pongmala C; Artusi CA; Romagnolo A; Rizzone MG; Zibetti M; Lopiano L
    Acta Neurol Scand; 2019 Aug; 140(2):157-161. PubMed ID: 31025312
    [TBL] [Abstract][Full Text] [Related]  

  • 24. An Observational Study of the Effect of Levodopa-Carbidopa Intestinal Gel on Activities of Daily Living and Quality of Life in Advanced Parkinson's Disease Patients.
    Krüger R; Lingor P; Doskas T; Henselmans JML; Danielsen EH; de Fabregues O; Stefani A; Sensken SC; Parra JC; Onuk K; Yegin A; Antonini A
    Adv Ther; 2017 Jul; 34(7):1741-1752. PubMed ID: 28631218
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety and effectiveness of levodopa-carbidopa intestinal gel for advanced Parkinson's disease: A large single-center study.
    Blaise AS; Baille G; Carrière N; Devos D; Dujardin K; Grolez G; Kreisler A; Kyheng M; Moreau C; Mutez E; Seguy D; Defebvre L
    Rev Neurol (Paris); 2020 May; 176(4):268-276. PubMed ID: 31668287
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Intraduodenal levodopa-carbidopa intestinal gel infusion improves both motor performance and quality of life in advanced Parkinson's disease.
    Chang FC; Kwan V; van der Poorten D; Mahant N; Wolfe N; Ha AD; Griffith JM; Tsui D; Kim SD; Fung VS
    J Clin Neurosci; 2016 Mar; 25():41-5. PubMed ID: 26777085
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Burden of non-motor symptoms in Parkinson's disease patients predicts improvement in quality of life during treatment with levodopa-carbidopa intestinal gel.
    Ray Chaudhuri K; Antonini A; Robieson WZ; Sanchez-Soliño O; Bergmann L; Poewe W;
    Eur J Neurol; 2019 Apr; 26(4):581-e43. PubMed ID: 30353942
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Starting with 24-h levodopa carbidopa intestinal gel at initiation in a large cohort of advanced Parkinson's disease patients.
    Szatmári S; Szász JA; Orbán-Kis K; Bataga S; Ciorba M; Nagy E; Neagoe R; Mihály I; Szász PZ; Kelemen K; Frigy A; Csipor-Fodor A; Constantin VA
    Sci Rep; 2024 Feb; 14(1):3676. PubMed ID: 38355970
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Do we start too late? Insights from the real-world non-interventional BALANCE study on the present use of levodopa/carbidopa intestinal gel in advanced Parkinson's disease in Germany and Switzerland.
    Weiss D; Ebersbach G; Möller JC; Schwarz J; Arlt C; Fritz B; Sensken SC; Eggert K
    Parkinsonism Relat Disord; 2022 Oct; 103():85-91. PubMed ID: 36087571
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impact of Disease Duration in Effectiveness of Treatment with Levodopa-Carbidopa Intestinal Gel and Factors Leading to Discontinuation.
    Regidor I; Santos-García D; Catalán MIJ; Puente V; Valldeoriola F; Grandas F; Mir P; Parra JC; Arbelo JM
    J Parkinsons Dis; 2019; 9(1):173-182. PubMed ID: 30562907
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Levodopa-carbidopa intestinal gel in advanced Parkinson's disease: final 12-month, open-label results.
    Fernandez HH; Standaert DG; Hauser RA; Lang AE; Fung VS; Klostermann F; Lew MF; Odin P; Steiger M; Yakupov EZ; Chouinard S; Suchowersky O; Dubow J; Hall CM; Chatamra K; Robieson WZ; Benesh JA; Espay AJ
    Mov Disord; 2015 Apr; 30(4):500-9. PubMed ID: 25545465
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Levodopa-Carbidopa Intestinal Gel Reduces Dyskinesia in Parkinson's Disease in a Randomized Trial.
    Freire-Alvarez E; Kurča E; Lopez Manzanares L; Pekkonen E; Spanaki C; Vanni P; Liu Y; Sánchez-Soliño O; Barbato LM
    Mov Disord; 2021 Nov; 36(11):2615-2623. PubMed ID: 34236101
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Diphasic dyskinesias during levodopa-carbidopa intestinal gel (LCIG) infusion in Parkinson's disease.
    Meloni M; Solla P; Mascia MM; Marrosu F; Cannas A
    Parkinsonism Relat Disord; 2017 Apr; 37():92-96. PubMed ID: 28063683
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-term effectiveness of levodopa-carbidopa intestinal gel in 177 Spanish patients with advanced Parkinson's disease.
    Valldeoriola F; Grandas F; Santos-García D; Regidor I; Catalán MJ; Arbelo JM; Puente V; Mir P; Parra JC
    Neurodegener Dis Manag; 2016 Aug; 6(4):289-98. PubMed ID: 27440190
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Transgastric Jejunostomy (PEG-J) for Continuous Infusion of Levodopa-Carbidopa Intestinal Gel: An Approach for Parkinson's Disease Treatment.
    Nomoto Y; Furihata M; Hagiwara H; Ishino H; Yano S; Okawa H; Nakatsu Y; Noda K; Nishi S; Ogiwara S; Kitamura T; Osada T
    Med Sci Monit; 2023 Aug; 29():e941285. PubMed ID: 37571821
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Levodopa/carbidopa intestinal gel infusion in advanced Parkinson's disease: a 7-year experience.
    Zibetti M; Merola A; Artusi CA; Rizzi L; Angrisano S; Reggio D; De Angelis C; Rizzone M; Lopiano L
    Eur J Neurol; 2014 Feb; 21(2):312-8. PubMed ID: 24313838
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Levodopa/carbidopa intestinal gel infusion and weight loss in Parkinson's disease.
    Fabbri M; Zibetti M; Beccaria L; Merola A; Romagnolo A; Montanaro E; Ferreira JJ; Palermo S; Lopiano L
    Eur J Neurol; 2019 Mar; 26(3):490-496. PubMed ID: 30347489
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-term effectiveness of levodopa-carbidopa intestinal gel on motor and non-motor symptoms in advanced Parkinson's disease: results of the Italian GLORIA patient population.
    Antonini A; Marano P; Gusmaroli G; Modugno N; Pacchetti C; Sensi M; Melzi G; Bergmann L; Zibetti M; Lopiano L
    Neurol Sci; 2020 Oct; 41(10):2929-2937. PubMed ID: 32342325
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Levodopa-carbidopa intestinal gel in the treatment of patients with Parkinson disease: results of a 12-month open study].
    Skoromets AA; Odinak MM; Yakupov EZ; Litvinenko IV; Zalyalova ZA; Timofeeva AA; Kirtaev SY; Bogdanov RR; Agafina AS; Chatamra K; Robieson W; Benesh J; Latypova GR; Ershova MV; Illarioshkin SN
    Zh Nevrol Psikhiatr Im S S Korsakova; 2017; 117(2):22-31. PubMed ID: 28374689
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comprehensive assessment of levodopa-carbidopa intestinal gel for Turkish advanced Parkinson’s disease patients.
    Sücüllü Karadağ Y; Saltoğlu T; Erdoğan Küçükdağli F; Öztürk Ö; Köseoğlu HT; Altiparmak E
    Turk J Med Sci; 2021 Feb; 51(1):84-89. PubMed ID: 32718129
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.